Abstract
Breast cancer is the most common malignancy in females. More than 1.7 million of cases are detected annually worldwide. The incidence of breast cancer in Russia has increased by 64 % over the last 20 years. There was a 1.43-fold increase in the prevalence of breast cancer (from 297 to 457cases per 100,000) between 2005 and 2017. A total of59,538 new cases were registered in the Russian Federation in 2012. In Russia, breast cancer is the most common malignancy among women aged 40—85years and the second most common cancer among women aged 15—39 (after cervical cancer). The disease is primarily detected in women aged between 40 and 54 years (29.5 %). More than 66,000 of new cases of breast cancer are registered in the Russian Federation annually. In 2017, there were 70,293 new cases of breast cancer; of them, 49,134 patients (69.9 %) hade stage I—II breast cancer. There was a 0.02 % increase in the proportion of new cases of stage I—II breast cancer in 2016—2017. For this reason, it is important to study in depth the markers of breast cancer used in everyday practice in order to personalize the treatment of patients with breast cancer.
Highlights
Analysis of new data for breast cancer markers used in routine practice
(2010) продемонстрировали, что Ki-67 является прогностическим у больных Рак молочной железы (РМЖ) при отсутствии поражения аксиллярных лимфатических узлов (ЛУ) (прогностическую значимость они подтверждают для рецепторов эстрогенов (РЭ)-положительных опухолей со II степенью злокачественности) [80]
Summary
После проведения многофакторного анализа молекулярных подтипов, лечения, размера опухоли, статуса регионарных ЛУ, степени злокачественности оказалось, что возраст по мере увеличения не оказывает негативного влияния на безрецидивную выживаемость и выживаемость, непосредственно связанную с заболеванием, в данной возрастной группе больных [31]. Исследователи установили, что для опухолей в группе больных до 40 лет были характерны факторы неблагоприятного течения болезни: более высокая степень злокачественности, большие размеры опухоли, большая частота гормонотрицательных опухолей.
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
